Advicenne SA logo

ADVIC - Advicenne SA News Story

€7.24 -0.3  -3.5%

Last Trade - 13/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £57.0m
Enterprise Value £43.0m
Revenue £1.50m
Position in Universe 554th / 852

BRIEF-Advicenne’S Flagship ADV7103 Receives Authorization For Pivotal Phase II/III Cystinuria Study In Belgium

Mon 7th January, 2019 4:53pm
Jan 7 (Reuters) - ADVICENNE SA  ADVIC.PA :
    * ADVICENNE’S FLAGSHIP ADV7103 RECEIVES AUTHORIZATION FOR
PIVOTAL
PHASE II/III CYSTINURIA STUDY IN BELGIUM
    * AUTHORIZATION EXTENDS PATIENT RECRUITMENT BASE OF EUROPEAN
PHASE
II/III CORAL STUDY, PREVIOUSLY AUTHORIZED IN FRANCE
    * DEVELOPMENTS WILL BE FINANCED WITH FUNDS RAISED BY
ADVICENNE,
WHICH CLOSED 2018 WITH A CASH POSITION OF MORE THAN 26 MEUR

Source text for Eikon:  ID:nBwb2ZfQ7a 
Further company coverage:  ADVIC.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.